EMPIRI's proprietary tumor tissue slice culture is a LDT (laboratory developed test) novel 3D culture method that maintains native cell:cell and cell:matrix interactions unique to individual patient's tumor. Our E-slice assay measures live tumor tissue treatment responses from patient tissues and experimental models, and has been validated in clinical studies to accurately predict individual patient responses.
The E-slice workflow
E-slices vs. the competition
Solutions for clinical research
We aim to transform the cancer care continuum by optimizing the drug development pipeline with specific, empirical treatment response data. Our E-slice Assay will provide pharmaceutical companies with a tool to increase the efficiency of clinical trials, accelerate the validation of novel therapies, and reduce healthcare costs.
The E-slice assay is a low cost, highly predictive technology that can accelerate and maximize clinical trials and drug discovery, providing empirical drug response data from a personalized therapy approach.
25% of cancer do not have standard of care treatments, but there are >240 FDA approved drugs. E-slice can identify potentially effective drugs for each patient.
Clinical trial selection
Clinical trials often provide the last chance for patients who don't respond to SOC. E-slice can identify the most effective trial drugs for each paient.
Standard of care selection
Multiple SOC drug combinations are approved for most cancer types but there is no way to know which is best for each patient. E-slice can provide important insights.
If you would like to learn more or invest, click here to email us.